Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

ABSTRACT: BACKGROUND:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions. RESULTS:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180?cm are at a 22% increased risk as compared to men with height <173?cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group. CONCLUSIONS:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.

SUBMITTER: Lophatananon A 

PROVIDER: S-EPMC5572182 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature